This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meyers, M. Articles by Boothman, D. A. Search for Related Content PubMed PubMed Citation Articles by Meyers, M. Articles by Boothman, D. A.

Role of the hMLH1 DNA Mismatch Repair Protein in Fluoropyrimidine-mediated Cell Death and Cell Cycle Responses¹

Department of Radiation Oncology and the Ireland Cancer Center, Laboratory of Molecular Stress Responses, Case Western Reserve University, Cleveland, Ohio 44106-4942

DNA mismatch repair (MMR) is an efficient system for the detection and repair of mismatched and unpaired bases in DNA. Deficiencies in MMR are commonly found in both hereditary and sporadic colorectal cancers, as well as in cancers of other tissues. Because fluorinated thymidine analogues (which through their actions might generate lesions recognizable by MMR) are widely used in the treatment of colorectal cancer, we investigated the role of MMR in cellular responses to 5-fluorouracil and 5-fluoro-2'-deoxyuridine (FdUrd). Human MLH1^- and MMR-deficient HCT116 colon cancer cells were 18-fold more resistant to 7.5 µM 5-fluorouracil (continuous treatment) and 17-fold more resistant to 7.5 µM FdUrd in clonogenic survival assays compared with genetically matched, MLH1⁺ and MMR-proficient HCT116 3–6 cells. Likewise, murine MLH1^- and MMR-deficient CT-5 cells were 3-fold more resistant to a 2-h pulse of 10 µM FdUrd than their MLH1⁺ and MMR-proficient ME-10 counterparts. Decreased cytotoxicity in MMR-deficient cells after treatment with various methylating agents and other base analogues has been well reported and is believed to reflect a tolerance to DNA damage. Synchronized HCT116 3-6 cells treated with a low dose of FdUrd had a 2-fold greater G₂ cell cycle arrest compared with MMR-deficient HCT116 cells, and asynchronous ME-10 cells demonstrated a 4-fold greater G₂ arrest after FdUrd treatment compared with CT-5 cells. Enhanced G₂ arrest in MMR-proficient cells in response to other agents has been reported and is believed to allow time for DNA repair. G₂ cell cycle arrest as determined by propidium iodide staining was not a result of mitotic arrest, but rather a true G₂ arrest, as indicated by elevated cyclin B1 levels and a lack of staining with mitotic protein monoclonal antibody 2. Additionally, p53 and GADD45 levels were induced in FdUrd-treated HCT116 3–6 cells. DNA double-strand break (DSB) formation was 2-fold higher in MMR-proficient HCT116 3–6 cells after FdUrd treatment, as determined by pulsed-field gel electrophoresis. The formation of DSBs was not the result of enhanced apoptosis in MMR-proficient cells. FdUrd-mediated cytotoxicity was caused by DNA-directed and not RNA-directed effects, because administration of excess thymidine (and not uridine) prevented cytotoxicity, cell cycle arrest, and DSB formation. hMLH1-dependent responses to fluoropyrimidine treatment, which may involve the action of p53 and the formation of DSBs, clearly have clinical relevance for the use of this class of drugs in the treatment of tumors with MMR deficiencies.

This article has been cited by other articles:

				I. Zlobec, K. Baker, L. M. Terracciano, and A. Lugli RHAMM, p21 Combined Phenotype Identifies Microsatellite Instability-High Colorectal Cancers with a Highly Adverse Prognosis Clin. Cancer Res., June 15, 2008; 14(12): 3798 - 3806. [Abstract] [Full Text] [PDF]

				D. S. Shewach and T. S. Lawrence Antimetabolite Radiosensitizers J. Clin. Oncol., September 10, 2007; 25(26): 4043 - 4050. [Abstract] [Full Text] [PDF]

				G. P. Kim, L. H. Colangelo, H. S. Wieand, S. Paik, I. R. Kirsch, N. Wolmark, and C. J. Allegra Prognostic and Predictive Roles of High-Degree Microsatellite Instability in Colon Cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study J. Clin. Oncol., March 1, 2007; 25(7): 767 - 772. [Abstract] [Full Text] [PDF]

				G. Lanza, R. Gafa, A. Santini, I. Maestri, L. Guerzoni, and L. Cavazzini Immunohistochemical Test for MLH1 and MSH2 Expression Predicts Clinical Outcome in Stage II and III Colorectal Cancer Patients J. Clin. Oncol., May 20, 2006; 24(15): 2359 - 2367. [Abstract] [Full Text] [PDF]

				F. V. Negri, A. Wotherspoon, D. Cunningham, A. R. Norman, G. Chong, and P. J. Ross Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer Ann. Onc., August 1, 2005; 16(8): 1305 - 1310. [Abstract] [Full Text] [PDF]

				M. Meyers, M. W. Wagner, A. Mazurek, C. Schmutte, R. Fishel, and D. A. Boothman DNA Mismatch Repair-dependent Response to Fluoropyrimidine-generated Damage J. Biol. Chem., February 18, 2005; 280(7): 5516 - 5526. [Abstract] [Full Text] [PDF]

				S Araki, S Israel, K S Leskov, T L Criswell, M Beman, D Y Klokov, L Sampalth, K E Reinicke, E Cataldo, L D Mayo, et al. Clusterin proteins: stress-inducible polypeptides with proposed functions in multiple organ dysfunction Br. J. Radiol., January 1, 2005; Supplement_27(1): 106 - 113. [Abstract] [Full Text] [PDF]

				T. Yan, A. B. Desai, J. W. Jacobberger, R. M. Sramkoski, T. Loh, and T. J. Kinsella CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responses Mol. Cancer Ther., September 1, 2004; 3(9): 1147 - 1157. [Abstract] [Full Text] [PDF]

				J. M. Mariadason, D. Arango, Q. Shi, A. J. Wilson, G. A. Corner, C. Nicholas, M. J. Aranes, M. Lesser, E. L. Schwartz, and L. H. Augenlicht Gene Expression Profiling-Based Prediction of Response of Colon Carcinoma Cells to 5-Fluorouracil and Camptothecin Cancer Res., December 15, 2003; 63(24): 8791 - 8812. [Abstract] [Full Text] [PDF]

				K. Kishi, Y. Doki, M. Yano, T. Yasuda, Y. Fujiwara, S. Takiguchi, S. Kim, I. Higuchi, and M. Monden Reduced MLH1 Expression after Chemotherapy Is an Indicator for Poor Prognosis in Esophageal Cancers Clin. Cancer Res., October 1, 2003; 9(12): 4368 - 4375. [Abstract] [Full Text] [PDF]

				D. Fallik, F. Borrini, V. Boige, J. Viguier, S. Jacob, C. Miquel, J.-C. Sabourin, M. Ducreux, and F. Praz Microsatellite Instability Is a Predictive Factor of the Tumor Response to Irinotecan in Patients with Advanced Colorectal Cancer Cancer Res., September 15, 2003; 63(18): 5738 - 5744. [Abstract] [Full Text] [PDF]

				S. Yanamadala and M. Ljungman Potential Role of MLH1 in the Induction of p53 and Apoptosis by Blocking Transcription on Damaged DNA Templates Mol. Cancer Res., August 1, 2003; 1(10): 747 - 754. [Abstract] [Full Text] [PDF]

				C. M. Ribic, D. J. Sargent, M. J. Moore, S. N. Thibodeau, A. J. French, R. M. Goldberg, S. R. Hamilton, P. Laurent-Puig, R. Gryfe, L. E. Shepherd, et al. Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer N. Engl. J. Med., July 17, 2003; 349(3): 247 - 257. [Abstract] [Full Text] [PDF]

				T. Yan, S. E. Berry, A. B. Desai, and T. J. Kinsella DNA Mismatch Repair (MMR) Mediates 6-Thioguanine Genotoxicity by Introducing Single-strand Breaks to Signal a G2-M Arrest in MMR-proficient RKO Cells Clin. Cancer Res., June 1, 2003; 9(6): 2327 - 2334. [Abstract] [Full Text] [PDF]

				R. A. Screaton, S. Kiessling, O. J. Sansom, C. B. Millar, K. Maddison, A. Bird, A. R. Clarke, and S. M. Frisch Fas-associated death domain protein interacts with methyl-CpG binding domain protein 4: A potential link between genome surveillance and apoptosis PNAS, April 29, 2003; 100(9): 5211 - 5216. [Abstract] [Full Text] [PDF]

				P. Taverna, H.-s. Hwang, J. E. Schupp, T. Radivoyevitch, N. N. Session, G. Reddy, D. A. Zarling, and T. J. Kinsella Inhibition of Base Excision Repair Potentiates Iododeoxyuridine-induced Cytotoxicity and Radiosensitization Cancer Res., February 15, 2003; 63(4): 838 - 846. [Abstract] [Full Text] [PDF]

				D. Machover, J. Zittoun, R. Saffroy, P. Broet, S. Giraudier, T. Magnaldo, E. Goldschmidt, B. Debuire, M. Orrico, Y. Tan, et al. Treatment of Cancer Cells with Methioninase Produces DNA Hypomethylation and Increases DNA Synthesis Cancer Res., August 15, 2002; 62(16): 4685 - 4689. [Abstract] [Full Text] [PDF]

				E. Raymond, S. Faivre, S. Chaney, J. Woynarowski, and E. Cvitkovic Cellular and Molecular Pharmacology of Oxaliplatin Mol. Cancer Ther., January 1, 2002; 1(3): 227 - 235. [Abstract] [Full Text] [PDF]

				P. Karran Mechanisms of tolerance to DNA damaging therapeutic drugs Carcinogenesis, December 1, 2001; 22(12): 1931 - 1937. [Abstract] [Full Text] [PDF]

				T. Yan, J. E. Schupp, H.-s. Hwang, M. W. Wagner, S. E. Berry, S. Strickfaden, M. L. Veigl, W. D. Sedwick, D. A. Boothman, and T. J. Kinsella Loss of DNA Mismatch Repair Imparts Defective cdc2 Signaling and G2 Arrest Responses without Altering Survival after Ionizing Radiation Cancer Res., November 1, 2001; 61(22): 8290 - 8297. [Abstract] [Full Text] [PDF]